Nonpharmacological Approach to Managing Atrial Fibrillation: A Review
Issue: 2023 - Volume 12 [Issue 4]
Francis C. Ifiora
Department of Pharmacy, University of Texas Health Science Center at Houston, Houston, USA.
Ginikachukwu M. Agudosi
Department of Internal Medicine, Trinity School of Medicine, Warner Robins, USA.
Chinwendum U. Ekpemiro
Department of Surgery, Federal Medical Centre, Umuahia, Nigeria.
Valentine C. Keke
Department of Internal Medicine, University of Nigeria, Enugu, Nigeria.
Department of Emergency Medicine, Lancashire Teaching Hospital, Preston, England.
Abiola Y. Oyesile
Department of Medicine, Dnipropetrovsk Medical Institute, Dnipropetrovsk, Ukraine.
Linda A. Mbah
Department of Internal Medicine, Veterans Affairs, Indiana, USA.
Ngozi T. Akueme
Department of Dermatology, University of Medical Sciences (UNIMEDTH), Ondo State, Nigeria.
Oyewole Emmanuel Akanle
Ladoke Akintola University of Technology, Ogbomosho, Oyo-State, Nigeria.
Imo State University, Owerri, Imo State, Nigeria.
Moses, Chukwuebuka Odoeke
University of Nigeria Nsukka, Nigeria.
Oba Okunade Sijuade College of Health Sciences Igbinedion University, Okada, Edo State, Nigeria.
Okelue E. Okobi *
Department of Family Medicine, Larkin Community Hospital, Palm Springs Campus, Miami, USA.
*Author to whom correspondence should be addressed.
Background: AF's global prevalence underscores its significance as a cardiac rhythm disorder that disrupts atrial activity, impairing normal cardiac function. Over five decades of study have illuminated the pathophysiological mechanisms underlying AF, including insights into re-entrant waves and macro-reentrant circuits. The emergence of non-uniform conduction patterns and bidirectional block regions has further enriched our understanding. Risk factors contributing to AF development encompass cardiovascular conditions, advanced age, and atrial structural changes. With its implications on stroke risk and cardiovascular health, AF has become a growing public health concern. The focus on AF epidemiology has expanded, with attention on the relationship between left atrial size and AF development. Individuals with larger left atria exhibit a heightened risk. Additionally, the elevated stroke risk associated with AF has been consistently documented.
To optimize clinical management, distinctions are drawn between chronic and paroxysmal AF, as well as the presence of structural heart disease. Mapping techniques have revealed insights into "atrial remodeling" and AF pathology. In managing AF, controlling heart rate, preventing clot formation, and restoring sinus rhythm are principal objectives. This article categorizes AF into acute, chronic, stable, or unstable forms, tailoring management approaches accordingly. While pharmacological interventions have shown efficacy, their limitations drive the exploration of nonpharmacological strategies. Approaches range from medications to cardioversion, including electrical and pharmacological methods.
Objective: This paper aimed to provide a comprehensive exploration of non-pharmacological approaches to AF management.
Methodology: This paper employed a structured methodology. This method involved a literature review, data synthesis, and critical analysis. During the literature review phase, we systematically searched electronic databases (PubMed, MEDLINE, Embase, and Google Scholar) for studies published from 1960 to 2023. Specific keywords and phrases such as "atrial fibrillation," "non-pharmacological interventions," "electrical cardioversion," "catheter ablation," "lifestyle modifications," "autonomic modulation," "left atrial appendage closure," and "exercise" were used. Our inclusion criteria encompassed studies addressing various non-pharmacological approaches for AF management, including observational studies and randomized controlled trials.
Result: The initial stage of our study involved the identification of a substantial number of relevant studies. We conducted a thorough literature search across multiple databases, using specific search terms and criteria relevant to our research topic. This comprehensive search yielded a total of 1,200 studies. After applying these stringent filtering criteria, we were left with 350 studies. To further refine our final sample and categorize the studies according to type, we conducted a detailed review of the remaining 350 studies. We categorized them into various types based on study design, methodology, and focus. We then also excluded studies with duplicate ideas and finally included 103 studies that addressed the objective of our research plan. (See reference list [1-103]).
Conclusion: This reviewed a number of non-pharmacological approaches including electrical cardioversion, catheter ablation, lifestyle modifications, autonomic modulation, left atrial appendage closure, and exercise, the paper delves into each method's advantages, potential risks, techniques, and efficacy. By offering this extensive overview, the article contributes to the expanding repository of knowledge on non-pharmacological approaches for AF management. These approaches offer potential for unique management of atrial fibrillations or in addition to pharmacologic management, may improve patient survivability or reduce complication outcomes.
In the management of Atrial fibrillation, choice between rhythm and rate control, lifestyle modifications, and patient adherence to treatment plans are critical factors influencing outcomes are factors to consider. Emerging therapies offer promise, but timely diagnosis, individualized care, and ongoing monitoring remain essential to improving AF patients' overall prognosis.
Keywords: Cardiovascular health, left atrial size, pathophysiological mechanisms, af management, cardiac arrhythmia, non-pharmacological approaches, atrial fibrillation
How to Cite
Nattel S. New ideas about atrial fibrillation 50 years on. (n.d.) Retrieved August 22. 2023415219.
Cox JL, Canavan TE, Schuessler, RB, et al.: The surgical treatment of atrial fibrillation: II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. The Journal of Thoracic and Cardiovascular Surgery. 1991; 101:406-426. DOI:10.1016/S0022-5223(19)36723-6
Lip G Tse H. Management of atrial fibrillation. The Lancet. 2007;370:604- 618. DOI:10.1016/S0140-6736(07)61300-2
Connolly S, Laupacis A. Gent M, RobertsR, Cairns, JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study.. Journal of the American College of Cardiology. 1991;18:349-355. DOI:10.1016/0735-1097(91)90585-W
Wakili R, Voigt N, Kääb S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8):2955-68. DOI: 10.1172/JCI46315
Nattel S, Burstein B, Dobrev. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circulation: Arrhythmia. 2008;1:62-73. DOI:10.1161/CIRCEP.107.754564
Zoni-BerissoM, Lercari F, Carazza T, Domenicucci S, Epidemiology of atrial fibrillation: European perspective. 2014;213:220. DOI:10.2147/CLEP.S47385
Leitz P, Stebel LM, Andresen C, Ellermann C, Güner F, Reinke F, Kochhäuser S, Frommeyer G, Köbe J, Wasmer K, Lange PS, Orwat S, Eckardt L, Dechering DG. Quantifying left atrial size in the context of atrial fibrillation ablation: Which echocardiographic method correlates to outcome of pulmonary venous isolation? J Pers Med. 2021;11(9):913. DOI: 10.3390/jpm11090913
Lip GY, Beevers, DG. ABC of atrial fibrillation: history, epidemiology, and importance of atrial fibrillation. Bmj. 1995;311:13-61. DOI:10.1136/bmj.311.7016.1361
Pritchett EL. Management of atrial fibrillation. New England Journal of Medicine. 1992;326:1264-1271. DOI:10.1056/NEJM199205073261906
Bianconi L, Mennuni M, Lukic V, Castr A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study. Journal of the American College of Cardiology. 1996;28:700-706. DOI:10.1016/0735-1097(96)00230-6
Crijns HJGM, Van Gelder IC, Lie KI. Benefits and risks of antiarrhythmic drug therapy after DC electrical cardioversion of atrial fibrillation or flutter. European Heart Journal. 1994;15:17-21. DOI:10.1093/eurheartj/15.suppl_A.17
Um KJ, McIntyre WF, Healey JS et al. Pre-and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: A systematic review and meta-analysis. EP Europace. 2019;21:856-863. DOI:10.1093/europace/euy310
de Paola A, Figueiredo E, Sesso R, Veloso HH, Nascimento LOT. Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation. International Journal of Cardiology. 2003;88:157-166. DOI:10.1016/S0167-5273(02)00380-7
Gentile F, Elhendy A, Khandheria BK. Safety of electrical cardioversion in patients with atrial fibrillation. In. Mayo Clinic Proceedings. 2002;77:897-904. DOI:10.4065/77.9.897
Själander S, Svensson PJ, Friberg L. Atrial fibrillation patients with CHA2DS2-VASc> 1 benefit from oral anticoagulation prior to cardioversion. International Journal of Cardiology. 2016;215:360-363. DOI:10.1016/j.ijcard.2016.04.031
Haegeli LM, Calkins H, Catheter ablation of atrial fibrillation: An update. European Heart Journal. 2014;35:2454-2459. DOI:10.1093/eurheartj/ehu291
Je HG, Shuman DJ, Ad N. A systematic review of minimally invasive surgical treatment for atrial fibrillation: A comparison of the Cox-Maze procedure, beating-heart epicardial ablation, and the hybrid procedure on safety and efficacy. European Journal of Cardio-Thoracic Surgery. 2015; 48:531-541. DOI:10.1093/ejcts/ezu536
Lall SC, Melby SJ, Voeller, RK, et al. The effect of ablation technology on surgical outcomes after the Coxmaze procedure: A propensity analysis. The. Journal of Thoracic and Cardiovascular Surgery. 2007;133:389- 396. DOI:10.1016/j.jtcvs.2006.10.009
Melby SJ, Zierer A, Bailey MS, Cox JL, Lawton JS, Munfakh N, Damiano Jr. RJ. A new era in the surgical treatment of atrial fibrillation: The impact of ablation technology and lesion set on procedural efficacy. Annals of Surgery. 2006;244:583. DOI:10.1097/01.sla.0000237654.00841.26
Stulak JM, Sundt III, TM, Dearani JA, Daly RC, Orsulak TA, Schaff HV. Ten-year experience with the Cox-maze procedure for atrial fibrillation: How do we define success?. The. Annals of Thoracic Surgery. 2006;83:1319-1324. DOI:10.1016/j.athoracsur.2006.11.007
Cox JL, Boineau JP, Schuessler RB, Kater KM, Lappas DG. Five-year experience with the maze procedure for atrial fibrillation. The. Annals of Thoracic Surgery. 1993;56:814-824. DOI:10.1016/0003-4975(93)90338-I
Hayward, RM, Upadhyay, GA, Mela, T, et al. Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and non-paroxysmal atrial fibrillation: A meta-analysis. Heart Rhythm. 2011;8:994-1000. DOI:10.1016/j.hrthm.2011.02.033
Da Costa A, Levallois M, Romeyer-Bouchard C, Bisch L, Gate-Martinet A, Isaaz K. Remote-controlled magnetic pulmonary vein isolation combined with superior vena cava isolation for paroxysmal atrial fibrillation: A prospective randomized study. Archives of Cardiovascular Diseases. 2015;108:163-171. DOI:10.1016/j.acvd.2014.10.005
Gula LJ, Skanes AC, Klein GJ, et al. Atrial flutter and atrial fibrillation ablation-sequential or combined? A cost-benefit and risk analysis of primary prevention pulmonary vein ablation. Heart Rhythm. 2016;13:1441- 1448. DOI:10.1016/j.hrthm.2016.02.018
Calvo N, Bisbal F, Guiu, E, et al. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. International Journal of Cardiology. 2013;168:4093-4097. DOI:10.1016/j.ijcard.2013.07.017
Forleo GB, Mantica M, De Luca L, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. Journal of Cardiovascular Electrophysiology. 2009; 20:22-28. DOI:10.1111/j.1540-8167.2008.01275
Ector J, Dragusin O, Adriaenssens B, et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. Journal of the American College of Cardiology. 2007;50:234-242. DOI:10.1016/j.jacc.2007.03.040
Li WJ, Bai, YY, Zhang, HY, et al. Additional ablation of complex fractionated atrial electrograms after pulmonary vein isolation in patients with atrial fibrillation: A meta-analysis. Circulation: Arrhythmia and Electrophysiology. 2011;4:143-148.
Bhargava M, Marrouche N, Martin DO, Schweikert RA, Saliba W, Saad EB, Natale A. Impact of age on the outcome of pulmonary vein isolation for atrial fibrillation using circular mapping technique and cooled‐tip ablation catheter: A retrospective analysis. Journal of Cardiovascular Electrophysiology. 2004; 15:8-13. DOI:10.1046/j.1540-8167.2004.03266.x
Mohanty S, Natale A, Mohanty P, et al. Pulmonary vein isolation to reduce future risk of atrial fibrillation in patients undergoing typical flutter ablation: Results from a randomized pilot study (REDUCE. 2015;26:819-825. DOI:10.1111/jce.12688
Nademanee, K, Amnueypol, M, Lee, F, et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm. 2015;12:44-51. DOI:10.1016/j.hrthm.2014.09.049
Wang RX, Lee HC, Hodge DO, et al. Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm. 2013;10:696- 701. DOI:10.1016/j.hrthm.2013.01.021
Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing. EP Europace. 2017;19:10-16. DOI:10.1093/europace/eux263
Tan ES, Rienstra M, Wiesfeld AC, Schoonderwoerd BA, Hobbel HH, Van Gelder IC. Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation. Europace; 2018. DOI:10:412-418. 10.1093/europace/eun020
Touboul P. Atrioventricular nodal ablation and pacemaker implantation in patients with atrial fibrillation. The. American Journal of Cardiology. 1999;83:241-245. DOI:10.1016/S0002-9149(98)01036-4
Ozcan C, Jahangir A, Friedman PA, et al. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. 2003;92:33-37. DOI:10.1016/S0002-9149(03)00460-0
Natale, A, Zimerman, L, Tomassoni, G, et al. : AV node ablation and pacemaker implantation after withdrawal of effective rate‐control medications for chronic atrial fibrillation: Effect on quality of life and exercise performance. Pacing and Clinical Electrophysiology. 1999;22:1634-1639. DOI:10.1111/j.1540- 8159.1999.tb00383.x
Ruiz‐Granell R, Morell‐Cabedo S, Ferrero‐de‐Loma A, García‐Civera R. Atrioventricular node ablation and permanent ventricular pacemaker implantation without fluoroscopy: Use of an electroanatomic navigation system. Journal of Cardiovascular Electrophysiology. 2005;16:793-795. DOI:10.1046/j.1540-8167.2005.40774.x
Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. Journal of the American College of Cardiology. 2006;48:1642-1648. DOI:10.1016/j.jacc.2006.05.072
Doshi RN, Daoud EG, Fellows C et al. Left Ventricular‐based cardiac stimulation post AV nodal ablation e valuation (The PAVE Study). Journal of Cardiovascular Electrophysiology. 2005;16:1160-1165. DOI:10.1111/j.1540-8167.2005.50062.x
Dickstein K, Bogale N, Priori S et al. The European cardiac resynchronization therapy survey . European Heart Journal. 2009;30:2450-2460. DOI:10.1093/eurheartj/ehp359
Leyva F, Nisam S, Auricchio A. Years of cardiac resynchronization therapy. JACC. 2014;64:1047-58.
Linde C, Ellenbogen K, McAlister, FA. Cardiac resynchronization therapy (CRT): Clinical trials, guidelines, and target populations. Heart Rhythm. 2012;9:3-13.
Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart failure events. New England Journal of Medicine. 2009;361:1329-1338. DOI:10.1056/nejmoa0906431
Bleeker, GB, Bax, JJ, Fung, JWH, et al.: Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. The American Journal of Cardiology. 2006;97:260-263. DOI:10.1016/j.amjcard.2005.08.030
Tang AS, Wells GA, Talajic M et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. New England Journal of Medicine. 2010;363:2385-2395. DOI:10.1056/nejmoa1009540
YU CM, Wing‐Hong Fung J, Zhang Q, Sanderson JE. Understanding nonresponders of cardiac resynchronization therapy—Current and future perspectives. Journal of Cardiovascular Electrophysiology. 2005; 16:1117-1124. DOI:10.1111/j.1540-8167.2005.40829.x
Castellant P, Fatemi M, Bertault-Valls V, Etienne Y, Blan JJ. Cardiac resynchronization therapy:“nonresponders” and “hyperresponders”. Heart Rhythm. 2008;5:193-197. 10.1016/j.hrthm.2007.09.023
Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: A feasibility study. Circulation: Arrhythmia and Electrophysiology. 2019;12:006934. DOI:10.1161/CIRCEP.118.006934
Middeldorp ME, Ariyaratnam J, Lau D, Sanders P,: Lifestyle modifications for treatment of atrial fibrillation. Heart. 2020;106:325-332. DOI:10.1136/heartjnl-2019-315327
Benjamin EJ, Al‐Khatib SM, Desvigne‐Nickens P, et al.: Research priorities in the secondary prevention of atrial fibrillation: A National Heart, Lung, and Blood Institute virtual workshop report; 2021 (ed). DOI:10.1161/JAHA.121.021566
Griffin JM, Stuart-Mullen LG, Schmidt MM, et al.: Preparation for and implementation of shared medical appointments to improve self-management, knowledge, and care quality among patients with atrial fibrillation. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2018;2:218-225. DOI:10.1016/j.mayocpiqo.2018.06.003
Qvist I, Lane DA, Risom SS, et al.: Implementation of patient education for patients with atrial fibrillation: Nationwide cross-sectional survey and one-year follow-up. European Journal of Cardiovascular Nursing, zvad066; 2023. DOI:10.1093/eurjcn/zvad066
Lau DH, Nattel S, Kalman JM, Sanders P,: Modifiable risk factors and atrial fibrillation . Circulation. 2017;136:583-596.
Sears SF, Anthony S, Harrell R, et al.: Managing atrial fibrillation: The intersection of cardiology, health psychology, and the patient experience. Health Psychology. 2022;41:792. DOI:10.1037/hea0001135
Lee SR, Ahn HJ, Choi EK, et al.: Improved prognosis with integrated care management including early rhythm control and healthy lifestyle modification in patients with concurrent atrial fibrillation and diabetes mellitus: A nationwide cohort study. Cardiovascular Diabetology. 2023; 22:18.
Chao TF, Joung B, Takahashi Y, et al.: Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: Executive summary. . Thrombosis and hemostasis. 2021;122:020-047. DOI:10.1055/s-0041-1739411
Weber C, Hung J, Hickling S, et al.: Incidence, predictors and mortality risk of new heart failure in patients hospitalized with atrial fibrillation. Heart. 2021;107:1320-1326. DOI:10.1136/heartjnl-2020-318648
Larsen RT, Gottliebsen CR, Wood KA, Risom SS,: Lifestyle interventions after ablation for atrial fibrillation: A systematic review. European Journal of Cardiovascular Nursing. 2020;19: 564-579. DOI:10.1177/1474515120919388
Mehta NK, Strickling J, Mark E, et al. : Beyond cardioversion, ablation and pharmacotherapies: Risk factors, lifestyle change and behavioral counseling strategies in the prevention and treatment of atrial fibrillation. 2021;66:2-9. DOI:10.1016/j.pcad.2021.05.002
Rosman L, Armbruster T, Kyazimzade S, et al. : Effect of a virtual self‐management intervention for atrial fibrillation during the outbreak of COVID‐19. Pacing and Clinical Electrophysiology. 2021;44:451-461. DOI:10.1111/pace.14188
Woo BF, Bulto LN, Hendriks JM, Lim TW, Tam WW,: The information needs of patients with atrial fibrillation: A scoping review. Journal of Clinical Nursing. 2023;32:1521-1533. DOI:10.1111/jocn.15993
Yang L, Chung MK,: Lifestyle changes in atrial fibrillation management and intervention. Journal of Cardiovascular Electrophysiology; 2023. DOI:10.1111/jce.15803
Bashir MU, Bhagra A, Kapa S, McLeod CJ,: Modulation of the autonomic nervous system through mind and body practices as a treatment for atrial fibrillation. Reviews in cardiovascular medicine. 2019;20:129-137. DOI:10.31083/j.rcm.2019.03.517
Goyal SK, Sharma A,: Atrial fibrillation in obstructive sleep apnea . World journal of cardiology. 2023;5:157.
Faulx MD, Mehra R, Geovanini GR, et al. : Obstructive sleep apnea and its management in patients with atrial fibrillation: An International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT) global survey of practicing cardiologists. IJC Heart & Vasculature. 2022;42:101085. DOI:10.1016/j.ijcha.2022.101085
Loomba RS, Arora R,: Obstructive sleep apnea and atrial fibrillation: A call for increased awareness and effective management. American Journal of Therapeutics. 2012;19:21-24.
Desteghe L, Hendriks JM, McEvoy RD, et al.: The why, when and how to test for obstructive sleep apnea in patients with atrial fibrillation. Clinical Research in Cardiology. 2018;107:617-631. DOI:10.1007/s00392-018- 1248-9
Ayas NT, Taylor CM, Laher I,: Cardiovascular consequences of obstructive sleep apnea . Current Opinion in Cardiology. 2016;31:599-605. DOI:10.1097/HCO.0000000000000329
Linz D, Baumert M, Desteghe L, et al.: Nightly sleep apnea severity in patients with atrial fibrillation: Potential applications of long-term sleep apnea monitoring. IJC Heart & Vasculature. 2019;24:100424. DOI:10.1016/j.ijcha.2019.100424
Iwasaki YK,: Mechanism and management of atrial fibrillation in the patients with obstructive sleep apnea. Journal of Arrhythmia. 2022; 38:974-980.
Fein AS, Shvilkin A, Shah D, et al.: Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. Journal of the American College of Cardiology. 2013;62:300-305. DOI:10.1016/j.jacc.2013.03.052
Linz D, McEvoy RD, Cowie MR, et al.: Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: A review. JAMA cardiology. 2018;3:532-540. DOI:10.1001/jamacardio.2018.0095
Gami AS, Somers VK : Implications of obstructive sleep apnea for atrial fibrillation and sudden cardiac death. Journal of cardiovascular electrophysiology. 2008;19: 997-1003. DOI:10.1111/j.1540-8167.2008.01136.x
Miller JD, Aronis KN, Chrispin J, et al.: Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. Journal of the American College of Cardiology. 2015;66:2899-2906. DOI:10.1016/j.jacc.2015.10.047
Kendzerska T, Gershon AS, Atzema C, et al.: Sleep apnea increases the risk of new hospitalized atrial fibrillation: A historical cohort study. Chest. 2018;154:1330-1339. DOI:10.1016/j.chest.2018.08.1075
Gami AS, Hodge DO, Herges RM, et al.: Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. Journal of the American College of Cardiology. 2007;49:565-571. DOI:10.1016/j.jacc.2006.08.060
Linz D, Brooks AG, Elliott AD, et al.: Variability of sleep apnea severity and risk of atrial fibrillation: The VARIOSA-AF study. JACC: Clinical Electrophysiology. 2019;5:692-701. DOI:10.1016/j.jacep.2019.03.005
Shukla A, Aizer A, Holmes D, et al.: Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: A meta-analysis. JACC: Clinical Electrophysiology. 2015;1:41-51. DOI:10.1016/j.jacep.2015.02.014
Marulanda-Londono E, Chaturvedi S,: The interplay between obstructive sleep apnea and atrial fibrillation. Frontiers in Neurology. 2017;8:668. DOI:10.3389/fneur.2017.00668/full
Kawai S, Mukai Y, Inoue S, et al.: Non-pulmonary vein triggers of atrial fibrillation are likely to arise from low-voltage areas in the left atrium. Scientific reports. 2019;9:12271-41598.
Gianni C, Mohanty S, Trivedi C, Di Biase L, Natale A: Novel concepts and approaches in ablation of atrial fibrillation: The role of non-pulmonary vein triggers. Ep Europace. 2018;20:1566-1576. DOI:10.1093/europace/euy034
Della Rocca DG, Mohanty S, Trivedi C, Di Biase L, Natale A,: Percutaneous treatment of non-paroxysmal atrial fibrillation: A paradigm shift from pulmonary vein to non-pulmonary vein trigger ablation?. Arrhythmia & Electrophysiology Review. 2018;7:256. DOI:10.15420/aer.2018.56.2
Santangeli P, Marchlinski FE,: Techniques for the provocation, localization, and ablation of nonpulmonary vein triggers for atrial fibrillation. Heart rhythm. 2017;14:1087-1096. DOI:10.1016/j.hrthm.2017.02.030
Della Rocca DG, Tarantino N, Trivedi C, et al.: Non‐pulmonary vein triggers in nonparoxysmal atrial fibrillation: Implications of pathophysiology for catheter ablation. Journal of cardiovascular electrophysiology. 2020;31:2154-2167. DOI:10.1111/jce.14638
Fukunaga M, Nagashima M, Korai K, et al.: Clinical impact of eliminating nonpulmonary vein triggers of atrial fibrillation and nonpulmonary vein premature atrial contractions at initial ablation for persistent atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2021;32:224-234. DOI:10.1111/jce.14830
Zhao Y, Di Biase L, Trivedi C, et al.: Importance of non-pulmonary vein triggers ablation to achieve long term freedom from paroxysmal atrial fibrillation in patients with low ejection fraction. Heart rhythm. 2016; 13:141-149.
Lin D, Frankel DS, Zado ES, et al.: Pulmonary vein antral isolation and nonpulmonary vein trigger ablation without additional substrate modification for treating longstanding persistent atrial fibrillation. Journal of cardiovascular electrophysiology. 2012;23:806-813. DOI:10.1111/j.1540-8167.2012.02307.x
Chang HY, Lo LW, Lin YJ, et al.: Long‐term outcome of catheter ablation in patients with atrial fibrillation originating from nonpulmonary vein ectopy. Journal of cardiovascular electrophysiology. 2013;24: 250-258. DOI:10.1111/jce.12036
Hung Y, Lo LW, Lin YJ, et al.: Characteristics and long-term catheter ablation outcome in long-standing persistent atrial fibrillation patients with non-pulmonary vein triggers. International Journal of Cardiology. 2017;241:205-211. DOI:10.1016/j.ijcard.2017.04.050
Stavrakis S, Kulkarni K, Singh JP, Katritsis DG, Armoundas AA,: Autonomic modulation of cardiac arrhythmias: Methods to assess treatment and outcomes. Clinical Electrophysiology. 2020;6:467-483. DOI:10.1016/j.jacep.2020.02.014
Hadaya J, Ardell JL,: Autonomic modulation for cardiovascular disease . Frontiers in physiology. 2020;11:617459. DOI:10.3389/fphys.2020.617459
Tsai WC, Hung TC, Kusayama T, et al.: Autonomic modulation of atrial fibrillation . jacc: Basic to translational science; 2023. DOI:10.1016/j.jacbts.2023.03.019
Arora R.: Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: Implications for therapies targeting the atrial autonomic nervous system. . Circulation: Arrhythmia and Electrophysiology. 2012;5:850-859. DOI:10.1161/CIRCEP.112.972273
Qin M, Zeng C, Liu X,: The cardiac autonomic nervous system: A target for modulation of atrial fibrillation. Clinical Cardiology. 2019; 42:644-652. DOI:10.1002/clc.23190
Stavrakis S, Scherlag BJ, Po SS.: Autonomic modulation: An emerging paradigm for the treatment of cardiovascular diseases. Circulation: Arrhythmia and Electrophysiology. 2022;5:247-248. DOI:10.1161/CIRCEP.112.972307
Mo BF, Zhang R, Yuan JL, et al.: Combined catheter ablation and left atrial appendage closure in atrial fibrillation patients with and without prior stroke. Journal of Interventional Cardiology. 2021;17:1533-1540. DOI:10.1093/europace/euv070
Reddy VY, Akehurst RL, Amorosi SL, Gavaghan MB, Hertz DS, Holmes Jr DR. : Cost-effectiveness of left atrial appendage closure with the WATCHMAN device compared with warfarin or non-vitamin K antagonist oral anticoagulants for secondary prevention in nonvalvular atrial fibrillation. Stroke. 2018;49: 1464-1470. DOI:10.1161/STROKEAHA.117.018825
Dar T, Yarlagadda B, Vacek J, Dawn B, Lakkireddy D.: Management of stroke risk in atrial fibrillation patients with bleeding on oral anticoagulation therapy-role of left atrial appendage closure, octreotide and more. Journal of Atrial Fibrillation. 2017;10:17-29. DOI:10.4022/jafib.1729
Dognin N, Salaun E, Champagne C, et al.: Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation. Journal of Interventional Cardiac Electrophysiology. 2021;1-13.
Wintgens L, Romanov A, Phillips K, et al.: Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. EP Europace. 2018;20: 1783-1789. DOI:10.1093/europace/euy025
Phillips KP, Pokushalov E, Romanov A, et al.: Combining watchman left atrial appendage closure and catheter ablation for atrial fibrillation: Multicentre registry results of feasibility and safety during implant and 30 days follow-up. . Ep Europace. 2018;20:949-955. DOI:10.1093/europace/eux183